168 related articles for article (PubMed ID: 29799812)
1. Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy.
Her EJ; Reynolds HM; Mears C; Williams S; Moorehouse C; Millar JL; Ebert MA; Haworth A
Phys Med Biol; 2018 Jun; 63(13):135011. PubMed ID: 29799812
[TBL] [Abstract][Full Text] [Related]
2. Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological models.
Miksys N; Haidari M; Vigneault E; Martin AG; Beaulieu L; Thomson RM
Med Phys; 2017 Aug; 44(8):4329-4340. PubMed ID: 28455849
[TBL] [Abstract][Full Text] [Related]
3. Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning.
Haworth A; Williams S; Reynolds H; Waterhouse D; Duchesne GM; Bucci J; Joseph D; Bydder S; Ebert M
Brachytherapy; 2013; 12(6):628-36. PubMed ID: 23871660
[TBL] [Abstract][Full Text] [Related]
4. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
[TBL] [Abstract][Full Text] [Related]
5. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
6. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
7. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
8. A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets.
Warkentin B; Stavrev P; Stavreva N; Field C; Fallone BG
J Appl Clin Med Phys; 2004; 5(1):50-63. PubMed ID: 15753933
[TBL] [Abstract][Full Text] [Related]
9. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
10. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.
Zaider M; Zelefsky MJ; Lee EK; Zakian KL; Amols HI; Dyke J; Cohen G; Hu Y; Endi AK; Chui C; Koutcher JA
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1085-96. PubMed ID: 10863082
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific voxel-level dose prescription for prostate cancer radiotherapy considering tumor cell density and grade distribution.
Zhao Y; Haworth A; Reynolds HM; Her EJ; Sun Y; Finnegan R; Rowshanfarzad P; Ebert MA
Med Phys; 2023 Jun; 50(6):3746-3761. PubMed ID: 36734620
[TBL] [Abstract][Full Text] [Related]
12. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.
Strigari L; Orlandini LC; Andriani I; d'Angelo A; Stefanacci M; Di Nallo AM; Benassi M
Phys Med Biol; 2008 Sep; 53(18):5045-59. PubMed ID: 18723926
[TBL] [Abstract][Full Text] [Related]
13. A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy.
Haworth A; Mears C; Betts JM; Reynolds HM; Tack G; Leo K; Williams S; Ebert MA
Phys Med Biol; 2016 Jan; 61(1):430-44. PubMed ID: 26675313
[TBL] [Abstract][Full Text] [Related]
14. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.
Keall PJ; Webb S
Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
16. The influence of the local effect model parameters on the prediction of the tumor control probability for prostate cancer.
Chanrion MA; Sauerwein W; Jelen U; Wittig A; Engenhart-Cabillic R; Beuve M
Phys Med Biol; 2014 Jun; 59(12):3019-40. PubMed ID: 24842293
[TBL] [Abstract][Full Text] [Related]
17. Prostate implant evaluation using tumour control probability--the effect of input parameters.
Haworth A; Ebert M; Waterhouse D; Joseph D; Duchesne G
Phys Med Biol; 2004 Aug; 49(16):3649-64. PubMed ID: 15446795
[TBL] [Abstract][Full Text] [Related]
18. Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression.
Fenwick JD
Phys Med Biol; 1998 Aug; 43(8):2159-78. PubMed ID: 9725596
[TBL] [Abstract][Full Text] [Related]
19. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
Nahum AE; Movsas B; Horwitz EM; Stobbe CC; Chapman JD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):391-401. PubMed ID: 12957250
[TBL] [Abstract][Full Text] [Related]
20. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.
Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ
Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
